Literature DB >> 7902572

Failure of a protective major histocompatibility complex class II molecule to delete autoreactive T cells in autoimmune diabetes.

R M Slattery1, J F Miller, W R Heath, B Charlton.   

Abstract

The association of major histocompatibility complex genes with autoimmune diseases is firmly established, but the mechanisms by which these genes confer resistance or susceptibility remain controversial. The controversy extends to the nonobese diabetic (NOD) mouse that develops disease similar to human insulin-dependent diabetes mellitus. The transgenic incorporation of certain class II major histocompatibility complex genes protects NOD mice from diabetes, and clonal deletion or functional silencing of autoreactive T cells has been proposed as the mechanism by which these molecules provide protection. We show that neither thymic deletion nor anergy of autoreactive T cells occurs in NOD mice transgenic for I-Ak. Autoreactive T cells are present, functional, and can transfer diabetes to appropriate NOD-recipient mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902572      PMCID: PMC47867          DOI: 10.1073/pnas.90.22.10808

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  A molecular basis for MHC class II--associated autoimmunity.

Authors:  J A Todd; H Acha-Orbea; J I Bell; N Chao; Z Fronek; C O Jacob; M McDermott; A A Sinha; L Timmerman; L Steinman
Journal:  Science       Date:  1988-05-20       Impact factor: 47.728

2.  A T cell receptor V beta segment that imparts reactivity to a class II major histocompatibility complex product.

Authors:  J W Kappler; T Wade; J White; E Kushnir; M Blackman; J Bill; N Roehm; P Marrack
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

3.  Deletion of self-reactive T cells before entry into the thymus medulla.

Authors:  H Hengartner; B Odermatt; R Schneider; M Schreyer; G Wälle; H R MacDonald; R M Zinkernagel
Journal:  Nature       Date:  1988-11-24       Impact factor: 49.962

4.  HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus.

Authors:  J A Todd; J I Bell; H O McDevitt
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

5.  The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique.

Authors:  H Acha-Orbea; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

Review 6.  T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens.

Authors:  H R MacDonald; R Schneider; R K Lees; R C Howe; H Acha-Orbea; H Festenstein; R M Zinkernagel; H Hengartner
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

Review 7.  What causes immunological nonresponsiveness?

Authors:  J Klein
Journal:  Immunol Rev       Date:  1984-10       Impact factor: 12.988

8.  Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice.

Authors:  H Nishimoto; H Kikutani; K Yamamura; T Kishimoto
Journal:  Nature       Date:  1987 Jul 30-Aug 5       Impact factor: 49.962

9.  Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus.

Authors:  B Charlton; A Bacelj; R M Slattery; T E Mandel
Journal:  Diabetes       Date:  1989-04       Impact factor: 9.461

10.  Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential.

Authors:  D Fowell; D Mason
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

2.  Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention.

Authors:  A J Demetris; N Murase; T E Starzl; J J Fung
Journal:  Graft (Georget Tex)       Date:  1998-05

3.  Abnormal T cell selection on nod thymic epithelium is sufficient to induce autoimmune manifestations in C57BL/6 athymic nude mice.

Authors:  V Thomas-Vaslin; D Damotte; M Coltey; N M Le Douarin; A Coutinho; J Salaün
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

4.  Genetic and physiological association of diabetes susceptibility with raised Na+/H+ exchange activity.

Authors:  G Morahan; P McClive; D Huang; P Little; A Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

5.  Disease-protected major histocompatibility complex Ea-transgenic non-obese diabetic (NOD) mice show interleukin-4 production not seen in susceptible Ea-transgenic and non-transgenic NOD mice.

Authors:  N Brenden; J Böhme
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

6.  Major histocompatibility complex class II molecules can protect from diabetes by positively selecting T cells with additional specificities.

Authors:  F Lühder; J Katz; C Benoist; D Mathis
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

7.  Major histocompatibility complex-linked control of autoimmunity.

Authors:  L S Wicker
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

8.  A mechanism for the major histocompatibility complex-linked resistance to autoimmunity.

Authors:  D Schmidt; J Verdaguer; N Averill; P Santamaria
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

9.  Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T cell response.

Authors:  W M Ridgway; H Ito; M Fassò; C Yu; C G Fathman
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

10.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

Authors:  D J Lenschow; S C Ho; H Sattar; L Rhee; G Gray; N Nabavi; K C Herold; J A Bluestone
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.